In connection with the completion of the merger, Dipexium effected a reverse stock split ... the date hereof only, and PLx specifically disclaims any duty or obligation to update forward-looking statements. 2017 DIPEXIUM
Protalix BioTherapeutics, Inc PLX was a big mover last session, as the company saw its shares rise 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which …
The Vietnamese stock markets experienced another strong selloff on Tuesday ... Bank for Investment and Development of Viet Nam (BID), petrol dealer Petrolimex …
Approximately 18.0 million shares, or approximately 40.0% of PLX's outstanding common stock, had been tendered as of 12:00 midnight at the end of the day on October 2, 2012. Correspondingly, in order for the trustee of the PLX Employee …
My Size, Inc. (NASDAQ: MYSZ) 14.6% LOWER; announced that it intends to …
Pluristem's PLacental eXpanded (PLX) cells are placenta-derived ... The Company is headquartered in Haifa, Israel. …
Dipexium said it will issue about 36 million new shares of its stock to PLx shareholders, who will own just under 77% of outstanding shares while current Dipexium shareholders will own a little over 23%. The new company will retain the …
Mr. Moshe Manor has been appointed President and Chief Executive Officer at Protalix BioTherapeutics, Inc. Mr. Manor has served as our President and Chief Executive Officer and as a director of our Company since November 2014. Mr. …
To use net proceeds from this offering, together with current cash resources, to advance aspertec 325 mg to market-readiness * Pricing of registered direct offering of 2.65 million shares of common stock at an offering price per share of …
Avago expects the acquisition to add immediately to non-GAAP earnings per share and anticipates “driving the PLX business to a level consistent with Avago’s long term business model by the end of fiscal year 2015.” Avago’s stock is …